SCHEMBL229062

SCHEMBL229062

COc1cc(NC(C)Cc2ccc(CCN3C4CCC3CC4)cc2)c(C2CCc3cc(O)ccc3C2)cc1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
DRD2 P14416 2/20 0.36
DRD1 P21728 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
CA9 Q16790 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP26A1 O43174 1/20 0.34
DHCR7 Q9UBM7 2/20 0.32
NR1I2 O75469 1/20 0.32
MAOA P21397 1/20 0.32
PTGS2 P35354 1/20 0.32
OPRK1 P41145 1/20 0.32
SLC6A3 Q01959 1/20 0.32
BCHE P06276 1/20 0.32
ABCB1 P08183 2/20 0.31
ABCC1 P33527 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL227144 0.91 ESR1 (0.40) ESR1ESR2DRD2DRD1SIGMAR1
SCHEMBL228077 0.89 ESR1 (0.51) ESR1ESR2DRD2CYP26A1DRD3
SCHEMBL227040 0.89 ESR1 (0.42) ESR1ESR2DRD2DRD1SIGMAR1
SCHEMBL228656 0.89 ESR1 (0.41) ESR1ESR2DRD2DRD1SIGMAR1
SCHEMBL225839 0.89 ESR1 (0.41) ESR1ESR2DRD2DRD1SIGMAR1
SCHEMBL227162 0.87 ESR1 (0.45) ESR1ESR2DRD2DRD1CA9
SCHEMBL225834 0.86 ESR1 (0.39) ESR1ESR2DRD2SIGMAR1DRD3
SCHEMBL229636 0.86 ESR1 (0.36) ESR1ESR2DRD2DRD1SIGMAR1
SCHEMBL229315 0.86 ESR1 (0.40) ESR1ESR2DRD2DRD1SIGMAR1
SCHEMBL229781 0.85 ESR1 (0.48) ESR1ESR2DRD2DRD1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399520-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2013-03-19 US disclosed
US-20120004315-A1 Selective Estrogen Receptor Modulator RADIUS HEALTH, INC. 2012-01-05 US disclosed
US-7960412-B2 Selective estrogen receptor modulator EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-06-14 US disclosed
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR RADIUS HEALTH, INC. 2009-12-31 US disclosed
US-7612114-B2 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer EISAI CO., LTD. (JP) 2006-06-01 US disclosed
EP-1577288-A1 SELECTIVE ESTROGEN RECEPTOR MODULATORS Eisai Co., Ltd. (JP) 2005-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325930-A1 SELECTIVE ESTROGEN RECEPTOR MODULATOR ESR1, GPER1, ESR2 ESR1 1/4885ESR2 3/4885DRD2 2301/4885
US-20060116364-A1 Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer BRCA1, BCR, RCC1 ESR1 34/4885ESR2 21/4885DRD2 2692/4885
US-20120004315-A1 Selective Estrogen Receptor Modulator ESR1, GPER1, ESR2 ESR1 1/4885ESR2 3/4885DRD2 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.